Woman Files Taxotere Baldness Lawsuit
The breast cancer treatment, Taxotere, may be more likely to cause permanent alopecia (hair loss) than other chemotherapy drugs. Today, Taxotere is one of the most common chemo drugs administered to breast cancer patients, both those with operable tumors and those with inoperable metastatic disease. It is a highly toxic chemotherapy agent, nearly double the toxicity of its close competitor, Taxol, a drug shown to be every bit as effective as Taxotere.
Taxotere is a chemotherapy agent that is usually administered in conjunction with other cancer drugs. In addition to breast cancer, the medication is indicated to treat head and neck cancer; gastric cancer, prostate cancer and non-small cell lung cancer.
Sanofi-Aventis is facing a growing number of lawsuits accusing the drug-maker of inadequately warning about the risk of permanent baldness. Before the label updates, the drug-maker reassured women that “hair generally grows back” after treatment. One can also navigate to www.taxoterehairlawsuit.com/taxotere-lawsuit-lawyers.aspx if you want to get information related to hairloss Lawsuits.
Hair loss is a well known side effect of chemotherapy, and Taxotere is no exception. Patients undergoing Taxotere treatment were led to believe that alopecia associated with its use would be temporary. However, it now appears that Taxotere may increase the risk of permanent hair loss.
Some of these women have even chosen to file lawsuits against the drug’s manufacturer, a French company called Sanofi, who they say has been hiding evidence of Taxotere’s link to permanent alopecia for years.